ID: ALA3350486

Max Phase: Preclinical

Molecular Formula: C44H81N3O15P2

Molecular Weight: 954.09

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O)OC(=O)CCCCCCCCCCCCCCC

Standard InChI:  InChI=1S/C44H81N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-39(48)57-33-36(60-40(49)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)34-58-63(53,54)62-64(55,56)59-35-37-41(50)42(51)43(61-37)47-32-31-38(45)46-44(47)52/h31-32,36-37,41-43,50-51H,3-30,33-35H2,1-2H3,(H,53,54)(H,55,56)(H2,45,46,52)/t36-,37-,41-,42+,43-/m1/s1

Standard InChI Key:  ITYHVANGBZMQML-VUYPABDGSA-N

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MPC-11 (12 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
L1210 (27553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
P388 (20296 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 954.09Molecular Weight (Monoisotopic): 953.5143AlogP: 9.11#Rotatable Bonds: 40
Polar Surface Area: 265.49Molecular Species: ACIDHBA: 16HBD: 5
#RO5 Violations: 3HBA (Lipinski): 18HBD (Lipinski): 6#RO5 Violations (Lipinski): 4
CX Acidic pKa: 1.86CX Basic pKa: CX LogP: 9.56CX LogD: 4.81
Aromatic Rings: 1Heavy Atoms: 64QED Weighted: 0.02Np Likeness Score: 0.84

References

1. Ryu EK, Ross RJ, Matsushita T, MacCoss M, Hong CI, West CR..  (1982)  Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.,  25  (11): [PMID:7143370] [10.1021/jm00353a010]
2. Hong CI, An SH, Schliselfeld L, Buchheit DJ, Nechaev A, Kirisits AJ, West CR..  (1988)  Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.,  31  (9): [PMID:3411602] [10.1021/jm00117a020]
3. Hong CI, An SH, Buchheit DJ, Nechaev A, Kirisits AJ, West CR, Berdel WE..  (1986)  Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.,  29  (10): [PMID:3761322] [10.1021/jm00160a041]

Source